Conversely, the MICA-129 homozygous allele A/A (Met/Met) variant was related to more advanced clinical characteristics, such as increased tumor invasion depth (T3/4; P = .0261, OR = 2.10), driver gene mutation (P = .0363, OR = 2.65), and KRAS mutation (P = .0392, OR = 2.23). The gene discussed is KRAS; the disease is neoplasm.